KRSNAA DIAGNOSTICS LIMITED INITIAL PUBLIC OFFERING TO OPEN UP ON AUGUST 04, 2021
- Price Band of Rs 933 to Rs 954 per equity share of the face value of Rs. 5 each (“Equity Shares”)
- Bid /Offer Opening Date – Wednesday, August 04, 2021, and Bid/ Offer Closing Date – Friday, August 06, 2021
- Minimum Bid Lot is 15 Equity Shares and in multiples of 15 Equity Shares thereafter
- The Floor Price is 186.6 times the face value of the Equity Shares and the Cap Price is 190.8 the face value of the Equity Shares.
Mumbai, August 02, 2021: Krsnaa Diagnostics Limited, is one of the largest differentiated diagnostic service providers in India (Source: CRISIL Report), proposes to open its Initial Public Offering on Wednesday, August 04, 2021.
The Price Band of the Offer has been fixed at Rs. 933 to Rs. 954 per Equity Share. Bids can be made for a minimum of 15 Equity Shares and in multiples of 15 Equity Shares thereafter. The Offer will close on Friday, August 06, 2021.
The Initial Public Offering comprises of a fresh issue aggregating up to ₹4,000.00 million (“Fresh Issue”) and an offer for sale of up to 8,525,520 Equity Shares (“Offered Shares”), comprising up to 1,600,000 Equity Shares Phi Capital Trust-Phi Capital Growth Fund-I, (“Selling Shareholder 1”), up to 3,340,713 Equity Shares by Kitara PIIN 1104 (“Selling Shareholder 2”), up to 3,563,427 Equity Shares by Somerset Indus Healthcare Fund I Limited (“Selling Shareholder 3”) and up to 21,380 Equity Shares by Lotus Management Solutions (acting through Mayur Sirdesai) (“Selling Shareholder 4”). The offer includes a reservation aggregating up to ₹200.00 million, for subscription by eligible employees (the “Employee Reservation Portion”).
This Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended (“SCRR”) read with Regulation 31 of the SEBI ICDR Regulations. This Offer is being made through the Book Building Process in accordance with Regulation 6(2) of the SEBI ICDR Regulations wherein, not less than 75% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers (“QIBs”) (the “QIB Portion”), provided that the Company in consultation with the BRLMs, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis (“Anchor Investor Portion”), out of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price, in accordance with the SEBI ICDR Regulations. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders (other than Anchor Investors), including Mutual Funds, subject to valid Bids being received at or above the Offer Price. If at least 75% of the Net Offer cannot be allotted to QIBs, the Bid Amounts received by the Company shall be refunded.
Further, not more than 15% of the Net Offer shall be available for allocation on a proportionate basis to Non-Institutional Bidders and not more than 10% of the Net Offer shall be available for allocation to Retail Individual Bidders (“RIBs”) in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. Further, Equity Shares aggregating up to ₹200.00 million will be available for allocation to Eligible Employees, subject to valid Bids being received at or above the Offer Price. All Bidders, other than Anchor Investors, are mandatorily required to participate in the Offer through the Application Supported by Blocked Amount (“ASBA”) process by providing details of their respective ASBA Account (as defined hereinafter), in which the corresponding Bid Amounts will be blocked by the Self Certified Syndicate Banks (“SCSBs”) or under the UPI Mechanism, as the case may be. Anchor Investors are not permitted to participate in the Anchor Investor Portion through the ASBA process
The Company proposes to utilize the net proceeds from the Fresh Issue (“Net Proceeds”) towards (i) Proposing to finance the cost of establishing diagnostics centers at Punjab, Karnataka, Himachal Pradesh, and Maharashtra; (2) Repayment/pre-payment, in full or part, of borrowings from banks and other lenders availed by the Company; and (3) General corporate purposes. JM Financial Limited, DAM Capital Advisors Limited (Formerly IDFC Securities Limited), Equirus Capital Private Limited, and IIFL Securities Limited are the book running lead managers to the issue The Equity Shares to be offered through the Red Herring Prospectus are proposed to be listed on BSE and NSE.
Krsnaa Diagnostics Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions, and other considerations, to make an initial public offering of its Equity Shares and has filed the Red Herring Prospectus dated July 29, 2021 (“RHP”) with Registrar of Companies, Maharashtra at Pune (“RoC”) and thereafter with Securities and Exchange Board of India (“SEBI”) and the Stock Exchanges. The RHP shall be available on the website of SEBI at www.sebi.gov.in, websites of the Stock Exchanges i.e. BSE and NSE at www.bseindia.com and www.nseindia.com, respectively, and is available on the websites of the BRLMs i.e. JM Financial Limited, DAM Capital Advisors Limited (Formerly IDFC Securities Limited), Equirus Capital Private Limited and IIFL Securities Limited at www.jmfl.com, www.damcapital.in, www.equirus.com, and www.iiflcap.com, respectively. Bidders should note that investment in equity shares involves a high degree of risk and for details refer to the RHP, including the section titled “Risk Factors” of the RHP when available. Potential Bidders should not rely on the Draft Red Herring Prospectus filed with SEBI for making any investment decision.
The Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) or any other applicable law of the United States and, unless so registered, may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. Accordingly, the Equity Shares are only being offered and sold (i) within the United States only to persons reasonably believed to be “qualiﬁed institutional buyers” (as deﬁned in Rule 144A under the Securities Act, “Rule 144A”) in transactions exempt from, or not subject to, registration requirements of the Securities Act, and (ii) outside the United States in offshore transactions in reliance on Regulation S under the Securities Act and pursuant to the applicable laws of the jurisdictions where those offers and sales are made. There will be no public offering of the Equity Shares in the United States